AAVantgarde Appoints New CFO to Drive Strategic Growth
Company - People | Apr 28, 2025 | Sofinnova Partners
AAVantgarde Bio, a clinical-stage biotechnology company known for its proprietary Adeno-Associated Viral (AAV) vector platforms, has appointed Rasmus Holm-Jorgensen as its new Chief Financial Officer. Holm-Jorgensen brings over 25 years of experience in the biopharmaceutical industry, including roles at Acrivon Therapeutics and Kiniksa Pharmaceuticals. He has a track record of driving growth and innovation, notably contributing to the $9 billion acquisition of Synageva BioPharma by Alexion. Reporting to CEO Dr. Natalia Misciattelli, Holm-Jorgensen will guide AAVantgarde's strategic and financial objectives during this pivotal time. AAVantgarde is focused on addressing the limitations of gene therapy cargo capacity with its platforms targeting Usher 1B and Stargardt disease.
Sectors
- Biotechnology
- Pharmaceuticals
Geography
- International – AAVantgarde is described as an international biotechnology company, indicating its operations and impact are not confined to a single country.
- Denmark – Rasmus Holm-Jorgensen is from Denmark and began his career at Novo Nordisk, a Danish company. He holds a degree from the University of Copenhagen.
Industry
- Biotechnology – AAVantgarde operates within the biotechnology sector, focusing on gene therapy solutions with proprietary viral vector platforms.
- Pharmaceuticals – This sector is relevant as AAVantgarde is involved in developing treatments for inherited retinal diseases.
Financials
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| AAVantgarde Bio | Target Company | Company | A biotechnology company focusing on gene therapy using proprietary AAV vector platforms. |
| Sofinnova Partners | Private Equity Firm | Company | A PE firm with a portfolio that includes AAVantgarde. |
| Rasmus Holm-Jorgensen | New CFO | Person | Appointed as CFO of AAVantgarde, with extensive experience in biopharmaceuticals. |
| Dr. Natalia Misciattelli | CEO | Person | Chief Executive Officer of AAVantgarde Bio. |